Dose-response effect of a 3-adrenergic receptor agonist , solabegron , on gastrointestinal transit , bowel function , and somatostatin levels in health April

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome.

  2008cited by this paper
• Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system.

  2007influential reference
• Challenges in drug development for functional gastrointestinal disorders. Part II: Visceral pain

  2006cited by this paper
• Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.

  2006cited by this paper
• Irritable bowel syndrome: recent and novel therapeutic approaches.

  2006cited by this paper
• Performance characteristics of scintigraphic transit measurements for studies of experimental therapies

  2002cited by this paper
• Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome

  2001cited by this paper
• Tonic Control of Peripheral Cutaneous Nociceptors by Somatostatin Receptors

  2001cited by this paper
• Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder.

  2001cited by this paper
• Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans.

  2000cited by this paper
• Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.

  2000cited by this paper
• Functional assessment of β adrenoceptor subtypes in human colonic circular and longitudinal (taenia coli) smooth muscle

  2000cited by this paper
• ATYPICAL β-ADRENOCEPTORS MEDIATING RELAXATION IN THE HUMAN COLON: FUNCTIONAL EVIDENCE FOR β3-RATHER THAN β4-ADRENOCEPTORS

  1999cited by this paper
• Localization of the β(beta)3‐adrenoceptor in the human gastrointestinal tract: an immunohistochemical study

  1998cited by this paper
• In vitro inhibition of human colonic motility with SR 59119A and SR 59104A: evidence of a beta3-adrenoceptor-mediated effect.

  1998cited by this paper
• Beta-3 adrenergic receptor agonists cause an increase in gastrointestinal transit time in wild-type mice, but not in mice lacking the beta-3 adrenergic receptor.

  1998cited by this paper
• Characterization of a beta 3-adrenoceptor stimulating gastrin and somatostatin secretions in rat antrum.

  1997cited by this paper
• Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets.

  1997cited by this paper
• Stool form scale as a useful guide to intestinal transit time.

  1997cited by this paper
• Functional evidence of atypical beta 3-adrenoceptors in the human colon using the beta 3-selective adrenoceptor antagonist, SR 59230A.

  1996cited by this paper
• Function and regulation of the beta 3-adrenoceptor.

  1996cited by this paper
• Inhibitory effects of SR 58611A on canine colonic motility: evidence for a role of β3‐adrenoceptors

  1995cited by this paper
• Tissue distribution of beta 3-adrenergic receptor mRNA in man.

  1993cited by this paper
• Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders.

  1992cited by this paper
• Towards a less costly but accurate test of gastric emptying and small bowel transit

  1991cited by this paper
• Assessment of functional gastrointestinal disease: the bowel disease questionnaire.

  1990cited by this paper
• Human gastric emptying and colonic filling of solids characterized by a new method.

  1989cited by this paper
• Contribution of the pancreas to circulating somatostatin-like immunoreactivity in the normal dog.

  1984cited by this paper

• No citing papers are available for this paper.